EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. - Wikidata - wikimedia - TriplyDB

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

http://www.wikidata.org/entity/Q33292103

about

Clinically and pharmacologically relevant interactions of antidiabetic drugs Multiple sclerosis and pregnancy: current considerations EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative [Diagnostics and treatment of polymyalgia rheumatica].Radiographic assessment of the femorotibial joint of the CCLT rabbit experimental model of osteoarthritis.How to integrate individual patient values and preferences in clinical practice guidelines? A research protocol.The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.Time trends in glucocorticoid use in rheumatoid arthritis: results from a population-based inception cohort, 1980-1994 versus 1995-2007.Medication-induced osteoporosis: screening and treatment strategies 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis.The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects Treating rheumatoid arthritis to target: the patient version of the international recommendations.The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses Impact of long-term steroid therapy on epicardial and pericardial fat deposition: a cardiac MRI study Incidence of Symptomatic Vertebral Fractures Among Newly Diagnosed Autoimmune Diseases Initiating Glucocorticoid Therapy.Bisphosphonates and glucocorticoid-induced osteoporosis: cons.Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis Glucocorticoid-induced osteoporosis: treatment update and review.Monitoring of patients on long-term glucocorticoid therapy: a population-based cohort study The Association between Systemic Glucocorticoid Use and the Risk of Cataract and Glaucoma in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study.Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)How to run a multiple sclerosis relapse clinic.Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?Brief Report: Patterns and Secular Trends in Use of Immunomodulatory Agents During Pregnancy in Women With Rheumatic Conditions.Glucocorticoids: complications to anticipate and prevent Hypertension in rheumatoid arthritis.Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis Insights into endocrine-immunological disturbances in autoimmunity and their impact on treatment Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug One-year effects of glucocorticoids on bone density: a meta-analysis in cohorts on high and low-dose therapy Differences between serum polar lipid profiles of male and female rheumatoid arthritis patients in response to glucocorticoid treatment.Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis.Conflicts of interest in biomedical publications: considerations for authors, peer reviewers, and editors.Lung Infections in Systemic Rheumatic Disease: Focus on Opportunistic Infections.

P2860

Q26752468-D3B2D344-C4D7-41BE-B786-004719EFCC91 Q26830133-10BF74CE-1E42-491E-9498-1DA4A7EA1316 Q26859134-B82A117B-786B-4D2C-A235-956B7B5271F6 Q28078550-40E60623-53D4-49CA-AD34-EC2923F91BEF Q28081356-9A76A0D7-C6F2-4199-8ECD-9FCCFEC926C7 Q30248636-F4E8D897-3944-42C5-A298-8EEBCA828847 Q33525369-D1AF4B99-0D7C-478C-9579-C0E2AF2C71D3 Q33669504-80BD0981-018E-49AA-B9B0-82837379E3DC Q33899182-3F93960A-FA58-4CAB-936E-8E282711F802 Q34110066-12FA9EC6-583E-4E0D-970D-907C5B5F7E67 Q34205665-77FB2FED-F4DD-459D-B3DA-8BCF0BBE1E2D Q34254377-01DFE253-5F2C-4A89-80F6-06F4CA3C9DF4 Q34389358-EFDB974F-7C9B-448D-857E-A9586CCFDDC0 Q34493588-3EA72999-2DBE-4BEC-8255-20C85164BC3C Q34548430-E3A39282-EC2C-4B12-8232-73C414EA9FFE Q34597321-0A1F5484-39C2-4FD0-9966-D26F1E101CAE Q34905363-7DF9D2E6-73A0-48D5-8E76-BC31BFF9D97C Q35617753-E371C408-5162-4013-88E6-B959B4041111 Q35792277-FEE84679-BF25-4000-9DB4-2292591E3332 Q35858075-561A995C-4A2C-4526-B2DF-5D4FCD610D14 Q35882427-C1CC3EAF-4A1B-4CC9-857B-620132E7DC23 Q36033348-9310AE14-1A2B-41CA-AB2D-96C8E247813D Q36059394-7A8F6452-D384-48F7-84CA-35130CD26256 Q36151251-187D3A96-7190-41ED-BF21-AE05C084FB20 Q36193029-68F95006-4C69-4581-A066-73D117F28032 Q36245964-D5ECC125-FFB5-4CF2-967D-20D10CE254C2 Q36557712-72392112-3784-4F45-A1BC-7F5E60563367 Q36577187-C6E2D28E-097D-4099-9AB5-D1A53CCD667A Q36705624-E9D2DB25-D500-4156-8B61-183A54827826 Q36844741-C2F972D9-0333-4F1F-97CE-CE3EDECBDA52 Q37052792-58F25F02-5FFD-4537-9E4E-2883B2AC4611 Q37158219-3920B2FC-F1F7-4DCB-A2CC-8E01385835D3 Q37169479-9D2600F7-4CBA-4696-92AD-ABF7B1EC0703 Q37206871-1C7826BE-5076-4A9C-B23C-7DF9322E4EEB Q37207076-07E8B210-4C2A-4DC2-8D0A-F53199D40056 Q37251693-F2E1CB3A-86FA-421A-BC77-C7D168B55A2C Q37429572-00A3AED6-1B97-4F6A-87D5-B1CC15141330 Q37484842-B66CC135-21E0-4712-BF7E-6FB31E647B55 Q37487299-3017D661-981F-427D-982A-EBF28C32F988 Q37690737-C67D274D-83D6-4BD7-A313-EDFAC95F378B

P2860

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

http://www.wikidata.org/entity/Q33292103

description

2007 nî lūn-bûn

@nan

2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

EULAR evidence-based recommend ...... therapy in rheumatic diseases.

@ast

EULAR evidence-based recommend ...... therapy in rheumatic diseases.

@en

EULAR evidence-based recommend ...... therapy in rheumatic diseases.

@nl

type

label

EULAR evidence-based recommend ...... therapy in rheumatic diseases.

@ast

EULAR evidence-based recommend ...... therapy in rheumatic diseases.

@en

EULAR evidence-based recommend ...... therapy in rheumatic diseases.

@nl

prefLabel

EULAR evidence-based recommend ...... therapy in rheumatic diseases.

@ast

EULAR evidence-based recommend ...... therapy in rheumatic diseases.

@en

EULAR evidence-based recommend ...... therapy in rheumatic diseases.

@nl

P1433

Q33292103-C3F36EA7-BE74-4F03-836A-DF674B076E67

P1476

Q33292103-1310A264-1392-4991-88DC-DBBD74D8C876

P2093

Q33292103-14068162-E0BA-4B68-9FF0-9388A89FF244

Q33292103-1C9AC75C-B9F1-4A5B-B37D-E38715EB57B4

Q33292103-1DF88FFE-3BB2-4782-93CF-547BFB0EAE10

Q33292103-219E1EF8-C999-4309-9472-7643E6603BAA

Q33292103-363116BF-8A77-448D-BE1F-9C2B6FBF407E

Q33292103-56B1779D-9317-4444-A6CE-973D4D5DF983

Q33292103-57E24059-85F8-4507-B9D5-39EEA2341A2E

Q33292103-5DC907A3-C180-4F5F-B9F4-03260DBBC501

Q33292103-64EC7698-2CED-4C8A-AB26-1574448351D0

Q33292103-76857768-2661-4405-BEE0-7B5BED3007DA

P2860

Q33292103-0B759A14-1007-4A20-B1A9-71EA8F8F714D

Q33292103-0E53B614-B1F2-4419-BACF-CE7C715EE9F4

Q33292103-123168CC-2373-4F0E-A8E7-F25ADBC3D24E

Q33292103-14009489-1D80-4DA5-BF80-11DAF626FBF2

Q33292103-1E747B3E-B86A-458A-BEE1-626F403406F6

Q33292103-2059F19A-65FE-4407-9CE5-EB94E98EBBF5

Q33292103-21286438-60DC-48E5-8D0B-BFD9380FA3DE

Q33292103-22839A6C-8A40-4B8F-8B43-BFCB70092CD7

Q33292103-2C0092A3-9B43-4327-A36A-596E0F7AD0EE

Q33292103-2D4B39F0-1517-418F-9EAC-B40792A748AD

P304

Q33292103-A266A1D2-D306-49CE-BC1C-9B3A967E0589

P31

Q33292103-D4E6DF17-9FC9-40BC-958D-C3EBCF8A3F53

P356

Q33292103-60B284CC-11A3-4719-8F72-B8EAA2233658

P407

Q33292103-7AF27467-C3F9-4031-BC27-09B8E8E14F08

P433

Q33292103-AEAC017B-30DB-4DB2-9CDE-08F5253502B6

P478

Q33292103-9FE249FD-1743-4B1D-9975-439098C8B6A8

P50

Q33292103-A10C431A-1A40-447E-BDCC-B285D95C9F99

P577

Q33292103-EDA313C4-9E87-4937-BC58-CA4C38A4D374

P5875

Q33292103-7FD56529-9796-423B-9153-B0AEAE91ED5A

P698

Q33292103-FF7B8A9A-7485-44E4-BD77-A53FBD7C9A9D

P921

Q33292103-5C439132-ACEF-41E1-ADEF-F320776FD75B

P932

Q33292103-B6970E82-0C34-4610-BD58-21CF55BB4988

P356

ARD.2007.072157

P1433

Annals of the Rheumatic Diseases

P1476

EULAR evidence-based recommend ...... therapy in rheumatic diseases

@en

P2093

A Russell

http://www.w3.org/2001/XMLSchema#string

B Svensson

http://www.w3.org/2001/XMLSchema#string

D Boumpas

http://www.w3.org/2001/XMLSchema#string

E H Choy

http://www.w3.org/2001/XMLSchema#string

F Buttgereit

http://www.w3.org/2001/XMLSchema#string

G Esselens

http://www.w3.org/2001/XMLSchema#string

H Zeidler

http://www.w3.org/2001/XMLSchema#string

I Hafstrom

http://www.w3.org/2001/XMLSchema#string

J N Hoes

http://www.w3.org/2001/XMLSchema#string

J R Kirwan

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of glucocorticoids on radiological progression in rheumatoid arthritis

Rofecoxib for rheumatoid arthritis

Treatments for gestational diabetes and impaired glucose tolerance in pregnancy

Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

P304

1560-1567

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.2007.072157

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P50

José Antonio da Silva

P577

2007-07-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6179242

http://www.w3.org/2001/XMLSchema#string

P698

17660219

http://www.w3.org/2001/XMLSchema#string

P921

P932

2095301

http://www.w3.org/2001/XMLSchema#string